<DOC>
	<DOCNO>NCT02450812</DOCNO>
	<brief_summary>This observational prospective single arm cohort study design ass overall survival , symptomatic skeletal event free survival quality life chemotherapy na√Øve metastatic Castration Resistant Prostate Cancer ( mCRPC ) patient receive Radium- 223 real life condition . In addition , time next tumor treatment ( TTNT ) , mobility , quality life selfcare , independence activity daily live safety assess .</brief_summary>
	<brief_title>Non-interventional Study With Ra-223 Dichloride Assessing Overall Survival Effectiveness Predictors mCRPC Patients Real Life Setting Germany</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Prostatic Neoplasms , Castration-Resistant</mesh_term>
	<mesh_term>Succinylcholine</mesh_term>
	<mesh_term>Radium Ra 223 dichloride</mesh_term>
	<criteria>Male patient diagnose castration resistant adenocarcinoma prostate ( CRPC ) symptomatic bone metastasis without know visceral metastasis Decision initiate treatment Radium223 make per investigator 's routine treatment practice Patients participate investigational program intervention outside routine clinical practice also noninterventional study focus Radium 223dichloride . Pretreatment cytostatics ( chemotherapy )</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>mCRPC</keyword>
</DOC>